Scholarlink

Background <p>Leukocytes have been reported to have tumor stimulating effects in colorectal cancer, among other malignancies. In line with this, earlier research has shown improved disease-free survival in patients with postoperative neutropenia compared to non-neutropenic patients following cytoreductive surgery (CRS) and hypertherm intraperitoneal chemotherapy (HIPEC).</p> Aim <p>To evaluate the impact of postoperative leukopenia after CRS and HIPEC on recurrence rate, survival, and risk of complications.</p> Methods <p>All CRS and HIPEC-procedures for colorectal adenocarcinoma in the national Swedish HIPEC-registry since 2015 and local registries in Uppsala and Malmö since 2003 until December 31st, 2021, were included (<i>n</i> = 921). Patients who did not complete a full CRS and HIPEC procedure (<i>n</i> = 99), had incomplete macroscopic cytoreduction (<i>n</i> = 25) or a lack of information on leukocyte count (<i>n</i> = 213) were excluded, resulting in 584 analyzed cases. Primary outcome was overall recurrence rate. Secondary outcomes were overall survival, recurrence-free survival, and perioperative complications.</p> Results <p>Postoperative leukopenia was observed in 54 (9.2%) cases of which 32 (5.5%) developed severe leukopenia. No differences in patient characteristics were noted between those with or without leukopenia. There were no differences in 3-year recurrence rate, overall survival or 3-year recurrence-free survival, between the groups. Neoadjuvant chemotherapy treatment, HR 1.32 (95% CI: 1.02–1.71), higher PCI-score, HR 1.50 (95% CI: 1.09–2.05) and higher pN-stage HR 2.52 (95% CI: 1.74–3.65) were associated with higher 3-year recurrence rate. 3-year mortality was associated with neoadjuvant chemotherapy treatment, HR 1.82 (95% CI: 1.06–3.11), severe postoperative complication, HR 2.39 (95% CI: 1.39–4.13) and high PCI-score, HR 2.60 (95% CI: 1.31–5.14). Treatment with combined oxaliplatin/irinotecan, HR 12.34 (95% CI: 4.51–33.74) was associated with developing postoperative leukopenia. Longer operation time, HR 2.30 (95% CI: 1.55–3.42), and severe leukopenia, HR 3.50 (95% CI: 1.25–9.77) were associated with postoperative complication.</p> Conclusions <p>Postoperative leukopenia did not impact recurrence rate or long-term survival in a statistically significant manner. Neoadjuvant chemotherapy and high PCI-score were associated with both recurrent disease and mortality within 3 years.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Postoperative leukopenia after cytoreductive surgery and hypertherm intraperitoneal chemotherapy for colorectal carcinomatosis– causes and implication on outcomes in a population-based study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月29日

查看全文
  • Mattias Lepsenyi,
  • Valentinus Valdimarsson,
  • Nader Algethami,
  • Henrik Thorlacius,
  • Lana Ghanipour,
  • Peter Cashin,
  • Dan Asplund,
  • Elinor Bexe Lindskog,
  • Gabriella Jansson Palmer,
  • Per J Nilsson,
  • Ingvar Syk

摘要

Background

Leukocytes have been reported to have tumor stimulating effects in colorectal cancer, among other malignancies. In line with this, earlier research has shown improved disease-free survival in patients with postoperative neutropenia compared to non-neutropenic patients following cytoreductive surgery (CRS) and hypertherm intraperitoneal chemotherapy (HIPEC).

Aim

To evaluate the impact of postoperative leukopenia after CRS and HIPEC on recurrence rate, survival, and risk of complications.

Methods

All CRS and HIPEC-procedures for colorectal adenocarcinoma in the national Swedish HIPEC-registry since 2015 and local registries in Uppsala and Malmö since 2003 until December 31st, 2021, were included (n = 921). Patients who did not complete a full CRS and HIPEC procedure (n = 99), had incomplete macroscopic cytoreduction (n = 25) or a lack of information on leukocyte count (n = 213) were excluded, resulting in 584 analyzed cases. Primary outcome was overall recurrence rate. Secondary outcomes were overall survival, recurrence-free survival, and perioperative complications.

Results

Postoperative leukopenia was observed in 54 (9.2%) cases of which 32 (5.5%) developed severe leukopenia. No differences in patient characteristics were noted between those with or without leukopenia. There were no differences in 3-year recurrence rate, overall survival or 3-year recurrence-free survival, between the groups. Neoadjuvant chemotherapy treatment, HR 1.32 (95% CI: 1.02–1.71), higher PCI-score, HR 1.50 (95% CI: 1.09–2.05) and higher pN-stage HR 2.52 (95% CI: 1.74–3.65) were associated with higher 3-year recurrence rate. 3-year mortality was associated with neoadjuvant chemotherapy treatment, HR 1.82 (95% CI: 1.06–3.11), severe postoperative complication, HR 2.39 (95% CI: 1.39–4.13) and high PCI-score, HR 2.60 (95% CI: 1.31–5.14). Treatment with combined oxaliplatin/irinotecan, HR 12.34 (95% CI: 4.51–33.74) was associated with developing postoperative leukopenia. Longer operation time, HR 2.30 (95% CI: 1.55–3.42), and severe leukopenia, HR 3.50 (95% CI: 1.25–9.77) were associated with postoperative complication.

Conclusions

Postoperative leukopenia did not impact recurrence rate or long-term survival in a statistically significant manner. Neoadjuvant chemotherapy and high PCI-score were associated with both recurrent disease and mortality within 3 years.